Search

Your search keyword '"Anita S Kablinger"' showing total 16 results
Start Over Author "Anita S Kablinger" Publisher elsevier bv
16 results on '"Anita S Kablinger"'

11. Hepatitis C screening, education, and linkage to care in an acute adult inpatient psychiatric unit

Author

Brynn S. Chavira, Marrieth Rubio, Varun Kesar, Aaditya Chandrasekar, Anita S. Kablinger, and Thomas Joseph

Subjects
Adult, Psychiatry, Linkage (software), Inpatients, medicine.medical_specialty, business.industry, Mental Disorders, Public health, Psychiatric Department, Hospital, Hepatitis C, Inpatient psychiatry, Integrated care, Unit (housing), Psychiatry and Mental health, Hepatitis C screening, medicine, Humans, Mass Screening, business, Patient education
Published
2020
Full Text
View/download PDF

12. HIV-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia: gene expression review

Author

Toni Kazic, Anita S. Kablinger, Roger E. Kelley, J. Steven Alexander, Raman Seth, Paul Shapshak, Elda M. Duran, and Alireza Minagar

Subjects
Psychosis, AIDS Dementia Complex, Multiple Sclerosis, business.industry, Gene Expression Profiling, Multiple sclerosis, Gene Expression, HIV Infections, Disease, medicine.disease, Degenerative disease, Neurology, Alzheimer Disease, Schizophrenia, medicine, Humans, Dementia, Neurology (clinical), Alzheimer's disease, business, Gene, Neuroscience, Oligonucleotide Array Sequence Analysis
Abstract

RNA and protein gene expression technologies are revolutionizing our view and understanding of human diseases and enable us to analyze the concurrent expression patterns of large numbers of genes. These new technologies allow simultaneous study of thousands of genes and their changes in regulation and modulation patterns in relation to disease state, time, and tissue specificity. This review summarizes the application of this modern technology to four common neurological and psychiatric disorders: HIV-1-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia and is a first comparison of these diseases using this approach.

Published
2004
Full Text
View/download PDF

13. Ramelteon-induced nightmares: A case report

Author

Chintan Shah and Anita S. Kablinger

Subjects
Adult, Male, Ramelteon, Receptors, Melatonin, Rapid eye movement sleep, Melatonin, Sleep Initiation and Maintenance Disorders, Melatonin agonist, Insomnia, medicine, Humans, Hypnotics and Sedatives, General Psychology, business.industry, Amphetamines, General Medicine, humanities, Dreams, Discontinuation, Psychiatry and Mental health, Indenes, Attention Deficit Disorder with Hyperactivity, Anesthesia, Central Nervous System Stimulants, medicine.symptom, business, medicine.drug
Abstract

Ramelteon is the only FDA-approved melatonin agonist for treatment of insomnia. It acts on melatonin MT1 and MT2 receptors. We describe a case of a patient who was prescribed ramelteon for insomnia disorder. Shortly after initiation of ramelteon, he described vivid nightmares leading to discontinuation of ramelteon. The nightmares ameliorated with ramelteon discontinuation. Ramelteon is well tolerated with a favorable side-effect profile. No documented cases of nightmares secondary to ramelteon use were found in the literature. The effects of ramelteon on rapid eye movement sleep, the stage of sleep where dreams occur, need to be further explored.

Published
2015
Full Text
View/download PDF

14. Blockade of glucose transporters by antipsychotic drugs

Author

Anita S. Kablinger, Arthur M. Freeman, D.S. Dwyer, and R.J. Bradley

Subjects
Pharmacology, business.industry, medicine.medical_treatment, Glucose transporter, Blockade, Psychiatry and Mental health, Neurology, medicine, Pharmacology (medical), Neurology (clinical), Antipsychotic, business, Biological Psychiatry
Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results